Procurement Must Look Beyond Price To Ensure Supply Chain Security
Criteria Must Reward Non-Price Aspects In Wake Of COVID-19
A globally co-ordinated approach to sourcing that rewards non-pricing criteria is imperative to bolster the security of the off-patent industry’s supply chain in the wake of the coronavirus pandemic, James Burt tells Generics Bulletin in the second part of our exclusive interview.
You may also be interested in...
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
European procurement models that focus solely on the lowest-cost generics are jeopardizing efforts to strengthen the supply chain and secure investments in local manufacturing, says Christoph Stoller, president of Medicines for Europe.